This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Prevention of Drug Rash From Certain Cancer Therapies Using Tretinoin Cream

This study has been withdrawn prior to enrollment.
(Study withdrawn due to volunteer disinterest in participating.)
Information provided by (Responsible Party):
Anna Chien, Johns Hopkins University Identifier:
First received: May 5, 2011
Last updated: April 21, 2014
Last verified: April 2014

This research is being done to study whether using of topical tretinoin can help prevent the common rash that patients often get while taking epidermal growth factor inhibitor (EGFR-I) medications such ascetuximab or erlotinib.

Patients taking EGFR-I medications often develop skin irritation and acne-like bumps on their face, chest, and other areas. This rash from EGFR-I's is often treated with moisturizers and topical or oral antibiotics. However, there has not yet been a study looking at a way to prevent this common side effect from occurring, and topical tretinoin may be useful in reducing the rash.

Tretinoin 0.025% cream is approved by the Food and Drug Administration (FDA) for the treatment of acne, acne scarring, and photodamage. It is not approved for use in preventing rashes associated with EGFR-I's.

Condition Intervention
Medication Reaction Drug: Tretinoin

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Prevention of Epidermal Growth Factor Receptor Inhibitor-Associated Dermatologic Toxicities by Pre-treatment With Topical Tretinoin

Resource links provided by NLM:

Further study details as provided by Anna Chien, Johns Hopkins University:

Primary Outcome Measures:
  • EGFRi rash severity [ Time Frame: 8 weeks ]

Enrollment: 0
Study Start Date: May 2011
Study Completion Date: March 2014
Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tretinoin pre-treatment Drug: Tretinoin
tretinoin 0.025% cream


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 years or over
  • Scheduled to begin treatment with an EGFR inhibitor drug

Exclusion Criteria:

  • Pregnant or nursing
  • History of bleeding disorder
  • History of keloids or large, thick, puffy-looking scars in the last 10 years
  • Used topical retinoids in the last year (e.g. tretinoin/Retin-A, adapalene/Differin, tazarotene/Tazorac)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01349556

Sponsors and Collaborators
Johns Hopkins University
Principal Investigator: Anna L Chien, MD Johns Hopkins Dermatology
  More Information

Responsible Party: Anna Chien, Assistant Professor, Co-Director, Cutaneous Translational Research Program, Johns Hopkins University Identifier: NCT01349556     History of Changes
Other Study ID Numbers: NA_00042104
Study First Received: May 5, 2011
Last Updated: April 21, 2014

Keywords provided by Anna Chien, Johns Hopkins University:
EGFR inhibitors
EGFRi drug rash

Additional relevant MeSH terms:
Drug-Related Side Effects and Adverse Reactions
Chemically-Induced Disorders
Antineoplastic Agents
Keratolytic Agents
Dermatologic Agents processed this record on August 23, 2017